NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zai Lab Limited (“Zai Lab” or the “Company”) ...

Just 3 months ago, I mentioned that my review at Old Teochew had me waking up the earliest. Well, my trip to Fei Zai Pork Rib ...

Zai Lab shows strong growth in oncology/autoimmune drugs; reduced losses and efficient operations evident in Q3 results. Healthy financial status with a strong current ratio of 7.68; reduced R&D ...

– Zocilurtatug pelitecan (zoci, DLL3 ADC) (formerly ZL-1310) data presented at Triple Meeting in October continues to demonstrate first- and best-in-class potential, supporting the recent initiation ...

While not a mind-blowing move, it is good to see that the Zai Lab Limited (NASDAQ:ZLAB) share price has gained 24% in the last three months. But that doesn't change the fact that the returns over the ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been dosed in a global Phase 2 clinical trial (NCT06380907) ...

The "Rule of 10" is a widely accepted yardstick within the biopharma industry for the chances of commercial success. According to the adage, it takes around 10 years and $1 billion to develop a viable ...

Zai Lab Limited announced that new data from its global Phase 1 trial of zocilurtatug pelitecan (ZL-1310), a DLL3-targeted therapy for extensive-stage small cell lung cancer, was selected for an oral ...